
A study compared the use of abiraterone alone versus abiraterone with concurrent androgen deprivation therapy (ADT) in patients with metastatic castration-resistant prostate cancer. The results showed that abiraterone alone had comparable efficacy in terms of prostate-specific antigen (PSA) response rates, PSA progression-free survival, and overall survival. The study suggests that further research is needed to explore the potential benefits and cost savings of using abiraterone alone.
Like
Save
Share